WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2005124361) USES OF GPR100 RECEPTOR IN DIABETES AND OBESITY REGULATION
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2005/124361    International Application No.:    PCT/GB2005/002434
Publication Date: 29.12.2005 International Filing Date: 21.06.2005
IPC:
G01N 33/556 (2006.01), C07K 14/705 (2006.01)
Applicants: PARADIGM THERAPEUTICS LIMITED [GB/GB]; 418 Cambridge Science Park, Milton Road, Cambridge CB4 0PA (GB) (For All Designated States Except US).
APARICIO, Samuel [PT/GB]; (GB) (For US Only).
DIXON, John [GB/GB]; (GB) (For US Only).
HENDRICK, Alan [IE/GB]; (GB) (For US Only).
HORWOOD, Jennifer, Marie [GB/GB]; (GB) (For US Only).
ZAHN, Dirk [DE/GB]; (GB) (For US Only)
Inventors: APARICIO, Samuel; (GB).
DIXON, John; (GB).
HENDRICK, Alan; (GB).
HORWOOD, Jennifer, Marie; (GB).
ZAHN, Dirk; (GB)
Agent: KHOO, Chong-Yee; D Young & Co, 120 Holborn, London EC1N 2DY (GB)
Priority Data:
0413872.3 21.06.2004 GB
60/586,618 09.07.2004 US
0423327.6 20.10.2004 GB
60/620,854 21.10.2004 US
Title (EN) USES OF GPR100 RECEPTOR IN DIABETES AND OBESITY REGULATION
(FR) RECEPTEUR
Abstract: front page image
(EN)We describe a method of identifying a molecule suitable for the treatment, prophylaxis or alleviation of a Gpr100 associated disease, in particular diabetes and obesity, the method comprising determining whether a candidate molecule is an agonist or antagonist of Gpr100 polypeptide, in which the Gpr100 polypeptide comprises the amino acid sequence shown in SEQ ID NO. 3 or SEQ ID NO. 5, or a sequence which is at least 90% identical thereto.
(FR)L'invention porte sur un procédé d'identification d'une molécule appropriée au traitement, à la prophylaxie ou au soulagement d'une maladie associée à Gpr100, en particulier le diabète et l'obésité : Le procédé consiste à déterminer si une molécule candidate est un agoniste ou un antagoniste du polypeptide Gpr100, le polypeptide Gpr100 comprenant la séquence d'acides aminés présentée dans le NO ID SEQ. 3 ou NO ID SEQ. 5 ou une séquence qui est au moins 90 % identique à celle-ci.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)